OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
33
Results
Show all
Save search
Copy query
Show results for
Unknown
(33)
Release Date
2018
(11)
2025
(4)
2017
(4)
2016
(4)
2021
(3)
2024
(2)
2023
(2)
2015
(2)
2014
(1)
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Not available
S-EPMC6568012
|
biostudies-literature
Cite
Genome-wide association study of prostate cancer-specific survival.
Not available
S-EPMC5674990
|
biostudies-literature
Cite
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Not available
S-EPMC6141445
|
biostudies-literature
Cite
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
Not available
S-EPMC4775252
|
biostudies-literature
Cite
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer.
Not available
S-EPMC4383163
|
biostudies-literature
Cite
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.
Not available
S-EPMC5995836
|
biostudies-literature
Cite
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Not available
S-EPMC4572072
|
biostudies-literature
Cite
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.
Not available
S-EPMC6075733
|
biostudies-literature
Cite
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.
Not available
S-EPMC5493145
|
biostudies-literature
Cite
Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma.
Not available
S-EPMC5643159
|
biostudies-literature
Cite
Previous
page
1 / 4
You're on page
1
page
2
page
3
page
4
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets